CAR T-Cell Therapy Ups Survival in Adults with Relapsed B-ALL (CME/CE)

(MedPage Today) -- In phase I data, median PFS 13 months; 20 months with low disease burden

Source: MedPage Today Hematology/Oncology - February 2, 2018 Category: Hematology Source Type: news